KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block
| Autor: | Juan Esteban Garcia-Robledo, Rafael Rosell, Alejandro Ruíz-Patiño, Carolina Sotelo, Oscar Arrieta, Lucia Zatarain-Barrón, Camila Ordoñez, Elvira Jaller, Leonardo Rojas, Alessandro Russo, Diego de Miguel-Pérez, Christian Rolfo, Andrés F. Cardona |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Pulmonary and Respiratory Medicine
Lung Neoplasms RC705-779 Review Proto-Oncogene Proteins c-met targeted therapy Proto-Oncogene Proteins p21(ras) resistance tumor genomics Diseases of the respiratory system non-small-cell lung cancer Carcinoma Non-Small-Cell Lung Mutation Biomarkers Tumor KRAS MET Humans biomarker directed therapy Pharmacology (medical) genomic profiling |
| Zdroj: | Therapeutic Advances in Respiratory Disease Therapeutic Advances in Respiratory Disease, Vol 16 (2022) |
| ISSN: | 1753-4666 |
| Popis: | Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor’s molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|